Jinan University and Guangzhou Lixin Pharmaceuticals have presented new 2-aminopyrimidine compounds acting as tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of cancer and inflammation.
Investigators from Emory University and affiliated organizations presented preclinical data for the IAP inhibitor AZD-5582 (AstraZeneca), which has previously demonstrated the ability to systemically reverse latency in animal models of HIV.
Protein functional sites usually include a small number of residues that are crucial for binding or catalytic functions. One approach for the design of proteins with new functions consists of designing an amino acid sequence that folds up to a 3D structure containing the site, given a functional site description from any source.
An effective universal vaccine ideally providing broad protection against all influenza A virus (IAV) subtypes with pandemic or zoonotic potential circulating in animals, as well as against antigenically variable seasonal strains, remains an urgent public health need.
A study led by researchers at the Institut Curie and INSERM has identified a means of overcoming CD8+ T-cell exhaustion and loss of cytotoxic activity in tumors.
Classic galactosemia (CG) is an inborn error of galactose metabolism caused by a severe deficiency of galactose-1-phosphate:uridylyltransferase (GALT) enzymatic activity, which leads to accumulation of several metabolites such as galactose-1-phosphate (Gal-1-P), the substrate of GALT, and galactonate and galactitol, the oxidation and reduction products.
Sosei Group Corporation and AbbVie have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.
Cellectis announced that the FDA has cleared its IND application to initiate a phase I/IIa clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
RSS